Hoersholm, Denmark; November 6th, 2015 - Medical Prognosis Institute A/S (MPI.CO) has in collaboration with Department of Molecular Disease Biology, University of Copenhagen, Denmark; Laboratory of Molecular Pharmacology, National Cancer Institute, USA; Linus Oncology, USA; Oncology Venture, Denmark and Department of Medical Chemistry and Molecular Pharmacology, Purdue University and the Purdue University Center for Cancer Research, USA published a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics under the title: "Targeting the topoisomerase 1 enzyme in cancer cells with acquired resistance to SN-38". Data from this scientific collaboration shows that LMP400 has topoisomerase 1 inhibitory activity, and that colon cancer and breast cancer could be target for clinical trials. TOP1 is among one of the important targets for use of the DRP(TM) technology. Oncology Venture - MPI's drug development arm is actively looking for a TOP1 product.
LMP400 is a topoisomerase 1 inhibitor (TOP1) from Linus Oncology which has shown promising pre-clinical data as LMP400 has demonstrated lack of cross resistance to the standard TOP1 anticancer drug Irinotecan. This means that LMP400 could be a potential new treatment alternative to patients who have experienced resistance to the standard chemotherapy Irinotecan.
"LMP400 targets TOP1 and TOP1 is a clinically relevant target for use of the DRP(TM) technology. Oncology Venture - MPI's drug development arm is actively looking for a TOP1 product." Says Adjunct professor Peter Buhl Jensen, M.D., CEO of MPI.
Link to poster !
About MPI Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.
About MPI's multiple biomarker called Drug Response Predictor - DRP(TM) MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 32 trials, where 26 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients' gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.
For further information, please contact Peter Buhl Jensen, CEO e-mail: pbj@medical-prognosis.com Cell Phone: +45 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark
HUG#1965162
